{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=20&state=Maryland",
    "query": {
      "state": "Maryland",
      "city": "Baltimore",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 13738,
    "total_pages": 1374,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=21&state=Maryland&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Baltimore&page=19&state=Maryland&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T05:41:34.412Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04080882",
      "title": "Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platysmal Bands"
      ],
      "interventions": [
        {
          "name": "AbobotulinumtoxinA dose 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AbobotulinumtoxinA dose 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AbobotulinumtoxinA dose 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2019-09-25",
      "completion_date": "2020-06-04",
      "has_results": true,
      "last_update_posted_date": "2022-08-26",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 8,
      "location_summary": "Encinitas, California • Encino, California • Boynton Beach, Florida + 4 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04080882"
    },
    {
      "nct_id": "NCT00354835",
      "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Rhabdomyosarcoma",
        "Childhood Alveolar Rhabdomyosarcoma",
        "Childhood Botryoid-Type Embryonal Rhabdomyosarcoma",
        "Childhood Embryonal Rhabdomyosarcoma",
        "Localized Childhood Soft Tissue Sarcoma",
        "Rhabdomyosarcoma",
        "Sarcoma",
        "Stage I Adult Soft Tissue Sarcoma AJCC v7",
        "Stage II Adult Soft Tissue Sarcoma AJCC v7",
        "Stage III Adult Soft Tissue Sarcoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dactinomycin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "Up to 49 Years"
      },
      "enrollment_count": 481,
      "start_date": "2006-12-26",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 196,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354835"
    },
    {
      "nct_id": "NCT02419989",
      "title": "PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "6 Years to 99 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-01",
      "completion_date": "2025-03",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02419989"
    },
    {
      "nct_id": "NCT06641089",
      "title": "Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Psoriatic"
      ],
      "interventions": [
        {
          "name": "Sonelokimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MoonLake Immunotherapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2024-10-15",
      "completion_date": "2027-09-13",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 44,
      "location_summary": "Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06641089"
    },
    {
      "nct_id": "NCT07059091",
      "title": "Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Allergies"
      ],
      "interventions": [
        {
          "name": "Omalizumab (Xolair®)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Chloride (NaCl) 0.9 %",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 334,
      "start_date": "2026-02-12",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07059091"
    },
    {
      "nct_id": "NCT07810790",
      "title": "Upper Extremity Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Functional Recovery",
        "Upper Extremity Vascularized Composite Allotransplantation"
      ],
      "interventions": [
        {
          "name": "Upper Extremity Vascularized Composite Allotransplantation (VCA)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2027-10",
      "completion_date": "2037-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07810790"
    },
    {
      "nct_id": "NCT07088913",
      "title": "A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-07-28",
      "completion_date": "2026-02-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07088913"
    },
    {
      "nct_id": "NCT06214923",
      "title": "Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain",
        "Virtual Reality",
        "Placebo",
        "Temporomandibular Disorder"
      ],
      "interventions": [
        {
          "name": "RelieVRx",
          "type": "DEVICE"
        },
        {
          "name": "Sham-VR",
          "type": "DEVICE"
        },
        {
          "name": "No-VR (natural history control)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "18 Years to 88 Years"
      },
      "enrollment_count": 78,
      "start_date": "2024-04-09",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06214923"
    },
    {
      "nct_id": "NCT01271790",
      "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Tegobuvir (GS-9190)",
          "type": "DRUG"
        },
        {
          "name": "GS-9451",
          "type": "DRUG"
        },
        {
          "name": "Pegasys®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Copegus®",
          "type": "DRUG"
        },
        {
          "name": "Tegobuvir placebo",
          "type": "DRUG"
        },
        {
          "name": "GS-9451 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 245,
      "start_date": "2010-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 85,
      "location_summary": "Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01271790"
    },
    {
      "nct_id": "NCT00198510",
      "title": "Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vitreous Hemorrhage",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Vitrase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 750,
      "start_date": "1998-11",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-15",
      "last_synced_at": "2026-11-06T05:41:34.412Z",
      "location_count": 61,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Chula Vista, California + 51 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198510"
    }
  ]
}